# Pathalys Pharma

**Canonical:** https://apis.io/providers/pathalys-pharma/  
**Website:** https://pathalys.com/  
**APIs profiled:** 7

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company headquartered at 4000 Center at North Hills Street, Raleigh, North Carolina, in the Research Triangle Park region. It was created with initial funding from Catalys Pacific and the DaVita Venture Group to be a multi-asset biopharmaceutical company focused on the needs of patients with end-stage kidney disease, and it develops advanced therapeutics addressing unmet needs in the management of late-stage chronic kidney disease (CKD). Its lead asset is upacicalcet, a novel non-peptide calcimimetic delivered intravenously by pre-filled syringe at the end of a hemodialysis session for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease on hemodialysis; it is an investigational product candidate in the United States, subject to FDA review. Pathalys raised $150 million in secured product financing and equity led by Abingworth in January 2023 alongside a development collaboration with Launch Therapeutics to run the pivotal PATH Phase 3 program, and closed an oversubscribed $105 million Series B in August 2024 to fund NDA submission and pre-commercialization. Pathalys runs no developer program and publishes no product API; the only machine-readable surface it exposes is the anonymously readable WordPress REST content API behind pathalys.com, which serves the corporate site, the news and scientific-updates stream, and the media library.

## Kin Score — 24.4 / 100 (emerging)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 24.4).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 14.1 |
| Governance | 4.5 |
| Contract Governance | 4.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 30.4 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 29.7 (agent-ready)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | verified |
| OpenAPI Examples | verified |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Open access — onboarding: open, pricing: unknown, trial: no (confidence: medium).

## APIs (7)

- **Pathalys Pharma Posts API** — Pathalys Pharma news, press releases and scientific updates
- **Pathalys Pharma Pages API** — Corporate pages — company, team, science, contact and legal
- **Pathalys Pharma Media API** — Media library — logos, team photography and press imagery
- **Pathalys Pharma Categories API** — Post categories and tags taxonomy
- **Pathalys Pharma Comments API** — Comments on posts (collection is empty on this site)
- **Pathalys Pharma Search API** — Cross-content search over posts and pages
- **Pathalys Pharma Discovery API** — Site index, route/namespace table, content types, taxonomies, statuses and oEmbed

## Security (2)

- **Pathalys Pharma Authentication** — 0 schemes
- **Pathalys Pharma Domain Security** — TLSv1.3 · DNSSEC · DMARC

## Plans (1)

- **Pathalys Pharma Plans Pricing**

## Tags

Company, Pharmaceuticals, Biotechnology, Nephrology, Chronic Kidney Disease, Clinical Trials, Life Sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/pathalys-pharma/). Scores are computed from the provider's own public artifacts under a published rubric.